Impact of <sup>18</sup> FDG-avidity and immunosuppression on idiopathic and genetic cardiomyopathies
Myocardial-only <sup>18</sup> FDG-avidity is only associated with adverse HF and arrhythmia outcomes in genotype-negative patients who do not clearly have CS. IST does not seem to modify the disease course, suggesting that not all myocardial <sup>18</sup> FDG uptake reflects clinically significant inflammation.
Authors
- Graham H. Bevan (ORCID: https://orcid.org/0000-0002-3756-7436)
- Neal A. Chatterjee (ORCID: https://orcid.org/0000-0002-8290-127X)
- Mallika Lal
- April S. Stempien-Otero
- Marcelo F. Di Carli (ORCID: https://orcid.org/0000-0003-3119-025X)
- ALEXI VASBINDER
- Benjamin Levin (ORCID: https://orcid.org/0009-0005-9946-0932)
- Babak Nazer
- Richard Cheng
- Esra Deniz Gumuser
- Stephen Hankinson
- Sanjay Divakaran
- Ron Blankstein
- Shiva Tabaghi
- Madison Pico
- Neal K Lakdawala
Institutions
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- University of Washington (US)
- Johnson University (US)
- Neurobehavioral Systems (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-02-03
- DOI
- https://doi.org/10.64898/2026.01.30.26345250
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00